Sumitomo Pharma : Announces Changes in Audit & Supervisory Board and Other Key Position
May 15, 2023
Share
Print(PDF/131KB)May 15, 2023Corporate
Sumitomo Pharma Announces Changes in Audit & Supervisory Board and Other Key Position
Sumitomo Pharma Co., Ltd. (Head Office: Osaka, Japan; Representative Director, President and CEO: Hiroshi Nomura) announced today that in its meeting held on May 15, 2023, the Board of Directors appointed the following candidate for new member of the Audit & Supervisory Board.
Changes in the Members of the Audit & Supervisory Board (as of June 27, 2023)
1.New Member of the Audit & Supervisory BoardHisayoshi Kashima (currently Senior Director, Finance & Accounting)
Note: The new member of the Audit & Supervisory Board who will take office as of June 27, 2023 is subject to the approval at the general shareholders' meeting scheduled for the same date.2.Retiring Member of the Audit & Supervisory BoardYoshinori Oh-e (currently Audit & Supervisory Board Member)
Sumitomo Pharma also announced the following Change in Personnel, effective June 27, 2023:
Position as of June 27, 2023
Current position
Name
Senior Director, Finance & Accounting
Chair of the Board and Chief Executive Officer, Sumitomo Pharma America Holdings, Inc.
Chair of the Board and Chief Executive Officer, Sumitomo Pharma America Holdings, Inc.
Koji Ishida
Reference
Brief Personal History of the candidate for new member of the Audit & Supervisory Board
Hisayoshi Kashima (Mr.) Birthdate: July 11, 1961
April 1985
Joined the former Sumitomo Pharmaceuticals Co., Ltd.
June 2007
Senior Director, Finance & Accounting, the Company
April 2012
Member, Board of Directors of Sumitomo Pharmaceuticals (Suzhou) Co., Ltd. (currently Sumitomo Pharma (Suzhou) Co., Ltd.)
April 2014
Senior Director, Finance & Accounting (to the present)
Reference
Members of the Board of Directors and the Audit & Supervisory Board after approval at the general shareholders' meeting (from June 27, 2023)
Board of Directors
Hiroshi Nomura
Representative Director, President and CEO
Toru Kimura
Representative Director, Executive Vice President
Yoshiharu Ikeda
Member, Board of Directors, Senior Executive Officer
Hiroyuki Baba
Member, Board of Directors, Senior Executive Officer
Shigeyuki Nishinaka
Member, Board of Directors, Senior Executive Officer
Sumitomo Pharma Co. Ltd. published this content on 15 May 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 08 June 2023 12:49:09 UTC.
Sumitomo Pharma Co., Ltd. (formerly Sumitomo Dainippon Pharma Co., Ltd.) specializes in development, manufacturing and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- pharmaceuticals (92.9%): for cardiovascular, gastrointestinal and infectious diseases, central nervous systems disorders and allergies treatment;
- other (7.1%): veterinary drugs, food additives, industrial chemical products, etc.
Net sales are distributed geographically as follows: Japan (39.8%), the United States (50.4%), North America (0.9%) and other (8.9%).